US 9,808,513 B2
Method of treatment of cancer using guanosine 3′, 5′ cyclic monophosphate (cyclic GMP)
David L. Vesely, Tampa, FL (US)
Assigned to UNIVERSITY OF SOUTH FLORIDA, Tampa, FL (US)
Filed by David L. Vesely, Tampa, FL (US)
Filed on Jun. 20, 2014, as Appl. No. 14/310,258.
Application 14/310,258 is a continuation of application No. 11/162,056, filed on Aug. 26, 2005, granted, now 8,759,317.
Application 11/162,056 is a continuation in part of application No. 10/708,688, filed on Mar. 18, 2004, granted, now 6,943,147, issued on Sep. 13, 2005.
Claims priority of provisional application 60/522,178, filed on Aug. 26, 2004.
Prior Publication US 2015/0018276 A1, Jan. 15, 2015
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/22 (2006.01); C07K 14/58 (2006.01); A61K 31/708 (2006.01); A61K 45/06 (2006.01); A61K 31/7076 (2006.01)
CPC A61K 38/2242 (2013.01) [A61K 31/708 (2013.01); A61K 31/7076 (2013.01); A61K 38/22 (2013.01); A61K 45/06 (2013.01); C07K 14/58 (2013.01); Y10S 930/05 (2013.01)] 23 Claims
 
1. A method of inhibiting the growth of a cancer cell in vivo comprising the steps of: contacting at least one target cancer cell in vivo with an effective amount of a cell permeable analog of cyclic guanosine monophosphate (GMP), or a composition comprising the cell permeable analog of cyclic GMP; and contacting the at least one target cancer cell in vivo with an effective amount of at least one peptide hormone selected from the group consisting of long acting natriuretic peptide, vessel dilator peptide, and kaliuretic peptide, or a composition comprising the at least one peptide hormone, whereby the growth of the at least one target cancer cell is inhibited, and wherein the target cancer cell is a sarcoma, small-cell carcinoma or squamous cell carcinoma.